Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).
-Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch-
-PADCEV with Keytruda® Potentially Practice Changing for First-Line.
Prozess Dreifachmord Starnberg: Was ist in der Tatnacht passiert? bild.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bild.de Daily Mail and Mail on Sunday newspapers.